[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-431220-105":59,"doc-detail-431220-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","correction-new-targets-in-diabetic-retinopathy-addressing-limitations-of-current-treatments-through-the-sema3anrp1-pathway","Correction - New targets in diabetic retinopathy - addressing limitations of current treatments through the Sema3A/Nrp1 pathway","","Correction notice for the Eye article titled “New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway.” During production, the “Plain Language Summary” and “Method of Literature Search” sections were omitted; this correction provides the missing text. It details PubMed search terms for diabetic retinopathy and related conditions and specifies included publication types, review and systematic evidence, manual selection from references, and searches on ClinicalTrials.gov and Google to identify upcoming DR trials. The original article is stated as corrected.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/correction-new-targets-in-diabetic-retinopathy-addressing-limitations-of-current-treatments-through-the-sema3anrp1-pathway/431220/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/correction-new-targets-in-diabetic-retinopathy-addressing-limitations-of-current-treatments-through-the-sema3anrp1-pathway/431220.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was omitted in the original Eye article during production?","Question",{"text":112,"@type":113},"The “Plain Language Summary” and “Method of Literature Search” sections were omitted during production.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the literature search conducted for the review?",{"text":117,"@type":113},"Background literature was searched in PubMed using terms covering diabetic retinopathy and related conditions, including semaphorin 3A and neuropilin 1, and relevant reference lists were manually reviewed and included.",{"name":119,"@type":110,"acceptedAnswer":120},"How were upcoming clinical trials identified?",{"text":121,"@type":113},"ClinicalTrials.gov and Google searches were performed to identify upcoming trials of DR treatments with potential to improve RNP.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},431220,1791106955,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","[www.nature.com/eye](www.nature.com/eye)  \nCORRECTION OPEN   \nCorrection: New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway  \nSobha Sivaprasad , Chui Ming Gemmy Cheung , Martin Gliem, Charles C. Wykoff, Nina Zippel, Susumu Ishida and Quan Dong Nguyen   \nEye (2026) 40:151; [https://doi.org/10.1038/s41433-025-03971-3](https://doi.org/10.1038/s41433-025-03971-3)  \nCorrection to: Eye [https://doi.org/10.1038/s41433-025-03835-w](https://doi.org/10.1038/s41433-025-03835-w), published online 09 July 2025  \nIn this article, the “Plain Language Summary” and “Method of Literature Search” have been omitted during the production process. They should read:  \nMethod of literature search  \nBackground literature was searched in PubMed using search terms such as ‘diabetic retinopathy’, ‘diabetic macular ischemia’,‘diabetic macular edema’, ‘semaphorin 3a’,‘neuropilin 1’, ‘retinal non-perfusion’, ‘vascular perfusion’, ‘anti-VEGF’, ‘corticosteroid’and ‘laser photocoagulation’. Selected articles in English included the following publication types: Clinical Study; Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Clinical Trial Protocol; Controlled Clinical Trial; Meta-Analysis, Randomised Controlled Trial; Review; and Systematic Review. Reference lists from the selected articles were also reviewed, from which relevant articles were manually included into the final list, in addition to extensive general background reading about the topic. Additionally, ClinicalTrials.-gov and Google searches were performed to identify upcoming trials of treatments in DR with the potential to improve RNP.  \nPlain language summary  \nThe retina is the light-sensing layer at the back of the eye. Damage to the retina can lead to eye diseases. Diabetes can cause reduced blood flow to the retina, damaging the retina and  \nleading to vision loss. Eye disease is common in people with diabetes. This review discusses different drugs currently used to treat sight loss in people with diabetes. Taking some of these drugs can affect the quality of a person’s life. For example, the treatment may need to be given by regular injections into the eye and/or may have upsetting side effects. This review also talks about new drugs now being studied to improve blood flow to theretina and slow or stop sight loss in people with diabetes. Proteins called semaphorin 3A and neuropilin 1 regulate blood flow to the retina. New drugs have been made that work against these proteins. These drugs may help to increase blood flow to the retina. Several other drugs that may increase blood flow to the retina are also being studied in animals and humans.  \nThe original article has been corrected.  \nOpen Access This article is licensed under a Creative Commons  \nAttribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecom](http://creativecom)[mons.org/licenses/by/4.0/](mons.org/licenses/by/4.0/) .  \n© The Author(s) 2025  \nPublished online: 7 November 2025","cbCairOATBPZv6gI","https://ap.wps.com/l/cbCairOATBPZv6gI","pdf",246842,"English","# Correction\n## Plain Language Summary\n## Method of Literature Search\n## Licensing and publication details","[{\"question\":\"What was omitted in the original Eye article during production?\",\"answer\":\"The “Plain Language Summary” and “Method of Literature Search” sections were omitted during production.\"},{\"question\":\"How was the literature search conducted for the review?\",\"answer\":\"Background literature was searched in PubMed using terms covering diabetic retinopathy and related conditions, including semaphorin 3A and neuropilin 1, and relevant reference lists were manually reviewed and included.\"},{\"question\":\"How were upcoming clinical trials identified?\",\"answer\":\"ClinicalTrials.gov and Google searches were performed to identify upcoming trials of DR treatments with potential to improve RNP.\"}]","Correction - New targets in diabetic retinopathy - addressing limitations of current treatments through the Sema3A/Nrp1 pathway | PDF",1790654842]